Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial

Eva Chalas, Chalas E, Costantino JP, Joseph P. Costantino, Wickerham DL, D. Lawrence Wickerham, Wolmark N, Norman Wolmark, Lewis GC, George C. Lewis, Cynthia Bergman, Bergman C, Carolyn D. Runowicz
American journal of obstetrics and gynecology · 2005 · vol. 192(4) , pp. 1230–1237 · doi:10.1016/j.ajog.2004.12.083 · PMID:15846210 · W2011246022
Non-randomised trial OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reports on the prevalence of benign gynecologic conditions observed in women participating in the Breast Cancer Prevention Trial.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project. STUDY DESIGN: The incidence rates of several benign gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs. Comparisons included stratification by menopausal status, body mass index, and history of estrogen use. RESULTS: Compared with women taking placebo, premenopausal women taking tamoxifen had a greater incidence of endometrial polyps (RR = 1.9, 95% CI = 1.55-2.41), leiomyomas (RR = 1.3, 95% CI = 1.14-1.55), endometriosis (RR = 1.9, 95% CI = 1.35-2.70), ovarian cysts (RR = 1.5, 95% CI = 1.20-1.78), and gynecologic surgical procedures, including hysterectomy (RR = 1.6, 95% CI = 1.29-1.88). Postmenopausal women taking tamoxifen also had an increased incidence of endometrial polyps (RR = 2.4, 95% CI = 1.76-3.24), leiomyomas (RR = 1.4, 95% CI = 1.04-1.80), endometriosis (RR = 1.9, 95% CI = 1.29-5.58), and gynecologic surgical procedures, including hysterectomy (RR = 2.2, 95% CI = 1.60-3.13), compared with women taking placebo. All women taking tamoxifen also had an increased incidence of simple endometrial hyperplasia without atypia (overall RR = 2.06, 95% CI = 1.64-2.60) compared with those taking placebo. CONCLUSIONS: Our results strongly support the estrogen agonist role of tamoxifen as the causative factor for the increased risk of endometrial polyps, leiomyomas, endometriosis, and endometrial hyperplasia among women taking this agent.

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Genital Diseases, Female Genital Diseases, Female Neoplasm Recurrence, Local Tamoxifen Adult Adult Aged Aged Age Distribution Age Distribution Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Breast Neoplasms Breast Neoplasms Breast Neoplasms Chemotherapy, Adjuvant Chemotherapy, Adjuvant

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (22)

Cited by (13)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:04.870308+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK